C2i Genomics, Riken Genesis to expand AI-powered whole-genome MRD cancer detection technology across Japan

New payment code and Medicare payment implemented for AI cancer imaging device

Avenda Health, an AI healthcare company, announced the Centers for Medicare & Medicaid Services has assigned a national payment rate for the company’s innovative prostate cancer mapping technology, Unfold AI.

July 26, 2024

Vol.50 No.30

Clinical Roundup

AI enhances physicians’ ability to identify extent of prostate cancer with 84% accuracy

Unfold AI is better at identifying cancer margins in the prostate than physicians identifying margins by sight, according to a new study. This AI improves accuracy from 67% to 84%, giving physicians more clarity and treatment planning, allowing them to better recommend therapies tailored to each patient.

July 19, 2024

Vol.50 No.29

Clinical Roundup

Exscientia builds AWS AI-powered platform to advance drug discovery

Exscientia plc announced it will be expanding its work with Amazon Web Services to use the cloud provider’s artificial intelligence and machine learning services to power its platform for end-to-end drug discovery and automation.

July 12, 2024

Vol.50 No.28

Clinical Roundup

Pan-cancer proteogenomics reveals potential drug targets

Researchers at Baylor College of Medicine and collaborating institutions have uncovered new potential therapeutic targets for cancer and new insights into existing cancer drug targets.

June 28, 2024

Vol.50 No.26

Drugs & Targets

Merck, Qure.ai collaborate to expand lung cancer detection via AI

Merck Global Health Innovation Fund has made a strategic investment into Qure.ai as part of its Series D round.

June 28, 2024

Vol.50 No.26

Clinical Roundup

AI tool helps to diagnose and predict severity of lung cancers

A computer program based on data from nearly a half-million tissue images and powered by artificial intelligence can accurately diagnose cases of adenocarcinoma, the most common form of lung cancer, a study published June 11 in Nature Communications shows.

June 14, 2024

Vol.50 No.24

C2i Genomics, Riken Genesis to expand AI-powered whole-genome MRD cancer detection technology across Japan

YOU MAY BE INTERESTED IN

New payment code and Medicare payment implemented for AI cancer imaging device

AI enhances physicians’ ability to identify extent of prostate cancer with 84% accuracy

Exscientia builds AWS AI-powered platform to advance drug discovery

Pan-cancer proteogenomics reveals potential drug targets

Merck, Qure.ai collaborate to expand lung cancer detection via AI

AI tool helps to diagnose and predict severity of lung cancers

Renew today!

Subscriber content

Login